Which new flu strain is going around Europe right now?
The new flu strain this winter is A(H1N1)pdm09 subclade D.3.1.1. A(H1N1)pdm09 now dominates in the EU/EEA, and nearly every virus sequenced in England and the United States belongs to D.3.1.1. Activity is still low: 2.8% of sentinel samples were positive in ERVISS week 43, down from 4.7%. No agency has called it more severe.
What is the dominant flu strain in Europe this week?
A(H1N1)pdm09 is the dominant flu strain in Europe in ERVISS week 43 (19 to 25 October 2026), and activity is low. ECDC's wording for the week is short: “Influenza and RSV activities remain low”. Of the sentinel influenza A viruses subtyped since week 40, 138 of 185 (75%) were A(H1N1)pdm09. That is the reverse of last winter, when A(H3N2) led.
The H1N1 viruses being sequenced belong to a single group, subclade D.3.1.1 of clade 5a.2a.1. That covers every sequenced A(H1N1)pdm09 virus in England so far (UKHSA, 29 October 2026). In the United States it covers 354 of 355 characterised viruses (CDC, 30 October 2026).
RSV is barely moving, at 0.4% positivity in the same sentinel samples. SARS-CoV-2 is busier, at 14.6%, and ECDC notes that its circulation “continues to increase in several countries”. Our page on COVID-19 symptoms and treatment covers that virus.
Is there a bad flu going around this winter?
Not on current evidence. Neither ECDC nor WHO has published a severity assessment of D.3.1.1. With 42 sentinel detections across the whole EU/EEA in week 43, there is little yet to assess. CDC's current line is that it is “too early to know what viruses may predominate” this season.
Last winter the equivalent WHO/Europe wording for subclade K was that “there is no evidence that it causes more severe disease”.
What people are calling it
There is no nickname yet. As of 2 November 2026 no health agency has given this autumn's H1N1 a popular name, and none has stuck in the press. The labels in circulation are technical: “A(H1N1)pdm09”, “subclade D.3.1.1” and “G155E”, the single surface-protein change virologists are watching.
A few US outlets say “mutated swine flu”: A(H1N1)pdm09 descends from the 2009 pandemic virus but has been a routine seasonal strain since.
Last winter's name was “super flu”. Journalists coined it for A(H3N2) subclade K in December 2025, after WHO/Europe said the strain made up “up to 90% of all confirmed influenza cases in the European Region”. The same statement said “there is no evidence that it causes more severe disease”. The nickname carried the first fact and dropped the second.
That is why nicknames mislead: a name describes a headline, not your risk. Last winter the answers were reassuring: no evidence of more severe disease, a vaccine that still lowered the risk of severe outcomes, no loss of antiviral sensitivity.
What is different about the new H1N1 strain?
The change is antigenic drift. Small mutations build up and let the virus slip past some of the immunity from earlier seasons. Three things are new this autumn: the subtype, one mutation and the vaccine.
The subtype has flipped. Subclade K is still circulating but outnumbered in every system that publishes sequences. In the United States 98.9% of influenza A viruses subtyped in week 42 were A(H1N1)pdm09.
One mutation is under the microscope. A subset of D.3.1.1 viruses carry G155E, a single change at position 155 of the haemagglutinin, the surface protein that antibodies lock onto. A US laboratory group tested blood from 355 people collected between April and August 2026 against 148 influenza viruses. D.3.1.1 viruses with this kind of change were neutralised less well, most clearly in teenagers and young adults.
The work is a preprint posted in September 2026 and has not yet been peer reviewed. UKHSA, citing WHO ferret-antisera results, reports “low reactivity of some viruses within the D.3.1.1 subclade”. It says it “is not yet clear how vaccine effectiveness against clinical disease may be affected by these observations”.
The vaccine was updated. WHO set the 2026/27 northern-hemisphere composition on 27 February 2026 with a new H1N1 reference virus, A/Missouri/11/2025, alongside A/Darwin/1454/2025 (H3N2) and B/Tokyo/EIS13-175/2025 (B/Victoria). How well it matches the new strain is covered below.
| Measure | Winter 2025/26 | Autumn 2026 |
|---|---|---|
| Dominant virus | A(H3N2) subclade K (formerly J.2.4.1) | A(H1N1)pdm09 subclade D.3.1.1 |
| EU/EEA season start | Passed 10% in week 46, three to four weeks before the two prior seasons | 2.8% in week 43; threshold not reached |
| Agency severity line | WHO/Europe: “no evidence that it causes more severe disease” | None published yet |
| Vaccine | Mismatch with subclade K; still lowered the risk of severe outcomes | H1N1 component updated; 94.2% of US H1N1 viruses well recognised |
| Antivirals | No reduced susceptibility found in A(H3N2) | 1.5% of US viruses with reduced inhibition by one antiviral; none to the others |
What are the flu symptoms this year?
Flu starts fast; this year's virus is no exception. The NHS description matches what our doctors see over video: symptoms “come on very quickly”. Typical signs are a sudden high temperature, an aching body, exhaustion, a dry cough, a sore throat, a headache, poor sleep and loss of appetite.
Speed is the tell: flu arrives “within a few hours” while a cold builds “over 1 to 2 days”. Nothing in the current ECDC, UKHSA or CDC reports describes a new symptom pattern for D.3.1.1.
The one-line split our doctors use:
- Cold: gradual, nose and throat, you can still function.
- Flu: sudden, fever, aches, exhaustion, floored within hours.
- COVID-19: can look like either; a test separates it from flu, symptoms alone do not.
The full comparison, with what each test can tell you, is in our cold, flu or COVID-19 comparison. Adults who suspect RSV can read our page on RSV in adults.
Can you get a rapid flu test at a pharmacy in Europe?
Yes, in several served countries. You can test for flu, COVID-19 and RSV with one swab at many European pharmacies. In France, pharmacists may perform rapid tests for influenza, COVID-19 and RSV, alone or combined, in the pharmacy itself. In Germany, combined self-test kits are sold over the counter in pharmacies.
Austrian and Dutch pharmacies and drugstores list them too. Elsewhere, ask for a “combi” or “triplex” kit, which reports each virus on its own line.
Test early. A rapid test is most useful in the first two days, because a positive result then changes what a doctor can do. Antiviral treatment works best when started within 48 hours of the first symptoms.
Our doctors never read a negative rapid test as proof you do not have flu. They weigh it against your symptoms, the timeline and the week's local positivity.
Do antivirals still work against this strain?
Yes, on current evidence. The drugs still work against the viruses tested this season, and timing matters more than the strain. Three antivirals are authorised for influenza in Europe, all prescription-only. ECDC's guidance is that they “should be taken within the first 48 hours of the symptom onset”.
CDC tested 537 influenza viruses collected in the United States since late May 2026. Eight A(H1N1)pdm09 viruses (1.5%) showed reduced inhibition by one of the drugs, and none by the others (CDC, 30 October 2026). UKHSA has recorded five detections of resistance-linked mutations in England so far this season, split between two of the three drugs.
Antivirals are often reserved for people at risk of complications. Our doctors prescribe an antiviral when it is appropriate: a patient in a risk group whose symptoms began within the last two days.
Outside a risk group our doctors advise self-care: rest and sleep, plenty of water, and paracetamol or ibuprofen for the fever and aches. Antibiotics do not work on flu.
Who qualifies in each European country, and what the three drugs do, is in our guide to flu antivirals in Europe. A longer guide to the first week is in how to recover from flu faster. Our approach is on our flu treatment over video page.
Does this year's flu vaccine match, and is it too late?
Mostly, and no, it is not too late. In CDC's latest testing, 97 of 103 (94.2%) A(H1N1)pdm09 viruses were well recognised by antisera to the new H1N1 reference virus. UKHSA's low-reactivity finding, above, leaves the effect on effectiveness unclear. Neither WHO nor ECDC has published a match statement for this season.
Last winter's vaccine was a clear mismatch for subclade K. ECDC's assessment described “a mismatch between the vaccine and this new subclade” and still expected protection against severe disease. WHO/Europe still reported that the vaccine “lowers the risk of severe health outcomes” from that virus.
The European season has not started in earnest. Last winter EU/EEA sentinel positivity passed 10% in week 46, three to four weeks earlier than the two previous seasons. It peaked at 47% in the last week of December and was still above 27% in week 6 of February. ECDC's advice last November was that vaccination “should proceed without delay”; nothing in this season's data changes that.
Mobi Doctor does not vaccinate: our doctors work over video and cannot give an injection. A pharmacy or local GP can. Our guide to getting a flu jab in Europe lists where it is given and who gets it free in all 12 countries.
Where is flu right now in Europe?
Flu activity is still low across the twelve countries Mobi Doctor serves, with Ireland and Romania the highest. The lines below are the ERVISS week 43 sentinel figures, published by ECDC on 30 October 2026. The current week's figures are on our live flu tracker for Europe, updated each Friday.
- Spain: 2.8% positive, ↓ from 4.2% (ERVISS week 43) · Spain flu tracker
- Germany: 4.3% in week 40 (latest ERVISS figure; weeks 41–43 not yet reported) · Germany flu tracker
- France: 2.6% positive, ↓ from 4.9% (ERVISS week 43) · France flu tracker
- Italy: no ERVISS sentinel figure yet this season (last entry week 9 of 2026) · Italy flu tracker
- Austria: 3.2% positive, → unchanged from 3.2% (ERVISS week 43) · Austria flu tracker
- Portugal: 0% positive on 17 samples, ↓ from 6.9% (ERVISS week 43) · Portugal flu tracker
- Greece: 6.7% in week 42, ↓ from 12.7%; week 43 not yet reported · Greece flu tracker
- Ireland: 11.8% in week 42, ↑ from 6.8%; week 43 not yet reported · Ireland flu tracker
- Netherlands: 3.3% positive, ↑ from 2.2% (ERVISS week 43) · Netherlands flu tracker
- Denmark: 5.2% positive, ↓ from 10.7% (ERVISS week 43) · Denmark flu tracker
- Luxembourg: 2.3% positive, ↓ from 4.6% (ERVISS week 43) · Luxembourg flu tracker
- Romania: 8.0% positive, ↑ from 7.7% (ERVISS week 43) · Romania flu tracker
EU/EEA overall: 2.8%, ↓ from 4.7%. For scale, the same week read 4.9% last year, 1.8% in 2024 and 1.9% in 2023. Sentinel samples are small in some countries, so one week can swing on a few swabs.
How long is flu contagious?
Roughly the first five days are the risky ones. The NHS puts it plainly: “You're more likely to give it to others in the first 5 days after getting infected”. Our calculator on how long flu stays contagious works it out from your symptom start date.
When to see a doctor
Call 112 at once if you or someone with you has sudden chest pain, severe difficulty breathing (gasping, choking or unable to speak), or is coughing up blood. These are the NHS emergency signs for flu; a video consultation is the wrong place for them.
See a doctor promptly, over video or in person, if you have flu symptoms and any of these apply:
- you are 65 or over
- you are pregnant or recently gave birth
- you have a long-term condition, such as diabetes or heart, lung, liver, kidney, brain or nerve disease
- you have a weakened immune system, for example from chemotherapy or HIV
- you feel very unwell or short of breath
- your symptoms have not improved after 7 days
For the risk groups the 48-hour antiviral window is the reason not to wait. A cough that outlasts the flu is covered in our guide to pneumonia after flu.
Children: Mobi Doctor sees adults only. A child with flu who worries you, above all over breathing, drowsiness or not drinking, needs the local paediatric service or 112. Hotel reception or the nearest pharmacy can point you to it.
What a video doctor can do
Our doctors see patients over video usually within 15 minutes, daily 7am–11pm CET, in all twelve countries listed above. Over video the doctor takes your history, watches how you breathe and speak, and checks when your symptoms started against the 48-hour window.
The doctor asks about risk factors and any rapid test result, and screens for the warning signs above. A prescription, when appropriate, is sent to a pharmacy you choose. Outside a risk group, or past 48 hours, the honest advice is usually self-care and a clear list of signs to watch.
What a video doctor cannot do: listen to your chest, measure your oxygen, X-ray, swab or vaccinate you. If you are breathless at rest, have chest pain or are getting worse after a week, you need to be seen in person. Where to go in each country is in our guide to urgent care across Europe.
Your plan if flu hits mid-trip
Note the hour your first symptom started; the 48-hour clock runs from there. Pick up a combined rapid test early. If you are in a risk group, or the test is positive, speak to a doctor over video before the window closes. Otherwise rest, drink and keep your distance for the first five days.
Pharmacies and surgeries keep different hours over the holidays. Our guide to finding a pharmacy or doctor over Christmas covers the holiday weeks.
Sources
- ECDC: Weekly respiratory virus update, week 43, October 2026 (accessed 2 November 2026)
- ECDC: ERVISS open data – sentinel tests, detections and positivity by country and week (EU-ECDC/Respiratory_viruses_weekly_data, week 43 release) (accessed 2 November 2026)
- CDC: Weekly US Influenza Surveillance Report (FluView), Key Updates for Week 42, ending October 24, 2026 (accessed 2 November 2026)
- UKHSA: National flu and COVID-19 surveillance report, 29 October 2026 (week 44) (accessed 2 November 2026)
- WHO: Recommendations for influenza vaccine composition for the 2026-2027 northern hemisphere season (27 February 2026) (accessed 2 November 2026)
- WHO/Europe: More than half of WHO European Region experiencing intense, early influenza season driven by new strain (17 December 2025) (accessed 2 November 2026)
- ECDC: Threat Assessment Brief – Assessing the risk of influenza for the EU/EEA in the context of increasing circulation of A(H3N2) subclade K (20 November 2025) (accessed 2 November 2026)
- ECDC: Antiviral treatment of influenza (Seasonal influenza – prevention and control) (accessed 2 November 2026)
- NHS: Flu (accessed 2 November 2026)
- Kikawa C, Bloom JD et al.: Near real-time data on the human neutralizing antibody landscape to influenza virus in summer of 2026 shows antigenic advance of H3N2 subclade K region D mutants and H1N1 D.3.1.1 Sa mutants (bioRxiv preprint posted 20 September 2026; PubMed record 42779881) (accessed 2 November 2026)
Written by the Mobi Doctor Medical Team. Medical review by Dr Chrysoula Liakou, MD, PhD: pending.